AstraZeneca is weighing a potential £300 billion merger with Bristol Myers Squibb amid questions about the long-term sustainability of its pharmaceutical innovation. The British-Swedish drugmaker has built a strong reputation for developing breakthrough cancer treatments like Imfinzi, Tagrisso, and Calquence under Chief Executive Sir Pascal Soriot. However, the impending expiration of patents on these flagship drugs by 2031 poses a significant challenge, as cheaper generics are expected to erode revenue.

While Soriot continues to express confidence in AstraZeneca’s scientific team based in Cambridge, some analysts and industry observers caution that maintaining the company’s historically high success rates in late-stage clinical trials may prove difficult. AstraZeneca’s recent phase three trial success rate has ranged between 85% and 90%, well above the industry average of around 60% to 65%. “People have got used to us delivering at a high success rate. But we have to accept we will fail from time to time,” Soriot acknowledged in recent comments.

The looming merger consideration may reflect a strategic response to this uncertainty rather than diminished faith in the company’s innovation capabilities. Experts point to the necessity of constant vigilance and adaptation in the pharmaceutical sector to sustain competitive advantage, echoing the principle that “only the paranoid survive.” Yet some analysts, including those at UBS, warn that large pharma mergers often lead to reduced research and development productivity, as concerns about job security can dampen scientists’ focus on innovation.

The challenge of continually fostering innovation is underscored by parallels observed in other companies. Novo Nordisk, once the pioneer of weight-loss drug Wegovy, has seen its stock lose two-thirds of its value since peaking in 2024, amid intensified competition and stalled innovation. Chief Executive Mike Doustdar has emphasized the need to embrace risk and accept failure as inherent parts of pharmaceutical development, warning against complacency and arrogance.

AstraZeneca’s Soriot has highlighted the need to operate with “Chinese speed” to remain competitive, referencing insights from Stanford research fellow Dan Wang on innovation-driven business culture in China. Wang points to the importance of “tacit knowledge”—the experiential understanding ingrained within manufacturing expertise—which China has preserved, while the United States and Europe have experienced a decline in this area. This industrial know-how, combined with a culture led by engineers focused not only on product but also on manufacturing efficiency, contributes to China’s rapid innovation pace.

Whether AstraZeneca’s potential mega-merger will bolster or hamper its innovative edge remains uncertain. As former General Electric CEO Jack Welch noted, sustained innovation requires an organizational culture committed to continual improvement. AstraZeneca faces the challenge of maintaining this ethos as it navigates patent cliffs, competitive pressures, and evolving global industry dynamics.